

## NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

## **DATA SHEET**

Catalog Number: 398

Lot Number: 110099

**Release** C

Category:

Provided:

1 vial cell-free virus (TCID<sub>50</sub>=1.15 x  $10^6$ /ml titered in PBMCs, HIV p24=11ng/ml).

**Original Source:** Human patient peripheral blood or bone marrow from patients with AIDS or related

diseases. Concentrated culture fluids of peripheral blood or bone marrow from several patients with AIDS or related diseases were used to establish a permanent productive

infection in a cloned permissive neo-plastic T cell line (H9).

Host Strain: H9 cells. Also infects other human neo-plastic CD4<sup>+</sup> T cells including CEM, U937, Molt 3,

HeLa CD4<sup>+</sup> cells, and human peripheral blood lymphocytes.

**Propagation:** Maintain cells in RPMI 1640 with L-glutamine, 80%; fetal bovine serum, 20% at 0.5-1 x

106cells/mL for optimal growth. Split 1:2 or 1:4 every 2-3 days.

**Sterility:** Negative for bacteria, mycoplasma, and fungi.

**Description:** X4 (SI).

Special

Characteristics:

High capacity to replicate in human T cell lines. This virus appears to be well adapted for *in vitro* culture in T cells and replicates less well in fresh human macrophages. It utilizes CXCR4 as a co-receptor. Host: H9. Also infects other human neo-plastic CD4+ T cells including CEM, U937, Molt 3, HeLa CD4+ cells, and human peripheral blood lymphocytes. Preparation: Maintain cells in RPMI 1640 with L-glutamine, 80%; fetal bovine serum, 20%

at  $0.5\text{-}1 \times 10^6$  cells/ml for optimum growth. Split 1:2-1:4 every 2-3 days.

Alternative Name: HTLV-III B/H9

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 06/19/2017 Page 1 of 2

Recommended Storage:

Liquid nitrogen.

**Contributor:** Dr. Robert Gallo.

References: Popovic M, Read-Connole E, Gallo RC. T4 positive human neoplastic cell lines susceptible

to and permissive for HTLV-III. Lancet ii: 1472-1473, 1984. Popovic M, Sarngadharan MG, Read E, Gallo, RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500,

1984. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR Jr, Pearson ML, Lautenberger JA, Papas TŚ, Ghrayab J, Chang NT, Gallo RC, Wong-Staal F. Complete nucleotide sequence of the AIDS virus, HTLV-III. *Nature* **313**:277-283, 1985.

NOTE: Acknowledgment for publications should read "The following reagent was obtained

through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB Virus from Dr. Robert Gallo." Also include the references cited above in any publications.

Scientist at for-profit institutions or who intend commercial use of this reagent

must contact Dr. Susan Ano, Office of Technology Transfer, National Institute of Health, 6011 Executive Blvd, Suite 325, Rockville, MD 20852, Tel:(301)

435-5515, Fax:(301) 402-0220, Email: anos@mail.nih.gov, Website:

http://ott.od.nih.gov, before the reagent can be released.

Last Updated: June 19, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 06/19/2017 Page 2 of 2